|
US20040082509A1
(en)
|
1999-10-12 |
2004-04-29 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US8183339B1
(en)
|
1999-10-12 |
2012-05-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US20030108539A1
(en)
*
|
2000-02-14 |
2003-06-12 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US7138496B2
(en)
*
|
2002-02-08 |
2006-11-21 |
Genetastix Corporation |
Human monoclonal antibodies against human CXCR4
|
|
US20040115184A1
(en)
*
|
2001-02-27 |
2004-06-17 |
Smith Harold C |
Methods and compositions for modifying apolipoprotein b mrna editing
|
|
EP1373308B1
(en)
|
2001-04-06 |
2006-10-25 |
Thomas Jefferson University |
Antagonist for multimerization of hiv-1 vif protein
|
|
DE60232672D1
(de)
|
2001-10-01 |
2009-07-30 |
Dyax Corp |
Mehrkettige eukaryontische display-vektoren und deren verwendungen
|
|
EP1487870A2
(en)
*
|
2002-01-09 |
2004-12-22 |
Université de Lausanne |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
|
US20050123973A1
(en)
*
|
2002-02-08 |
2005-06-09 |
Shaobing Hua |
Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
|
|
CA2495478A1
(en)
*
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US7220554B2
(en)
*
|
2003-05-23 |
2007-05-22 |
Oregon Health And Science University |
Methods for identifying inhibitors
|
|
US20050014137A1
(en)
*
|
2003-07-17 |
2005-01-20 |
Agouron Pharmaceuticals, Inc. |
Lentivirus assay system including Vif protein activity
|
|
US20050112555A1
(en)
*
|
2003-09-03 |
2005-05-26 |
Smith Harold C. |
Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
|
|
WO2005047483A2
(en)
*
|
2003-11-12 |
2005-05-26 |
Medical Research Council |
Renta: an hiv immunogen and uses thereof
|
|
WO2005115410A2
(en)
*
|
2004-05-06 |
2005-12-08 |
University Of Rochester |
Context dependent inhibitors of cytidine deaminases and uses thereof
|
|
CA2596448A1
(en)
|
2005-02-11 |
2006-08-11 |
University Of Rochester |
Methods and compositions related to heightened apobec-1 related protein (arp) expression
|
|
US8080517B2
(en)
|
2005-09-12 |
2011-12-20 |
Xigen Sa |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
WO2007031098A1
(en)
|
2005-09-12 |
2007-03-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
|
US8334255B2
(en)
*
|
2006-12-06 |
2012-12-18 |
Thomas Jefferson University |
Peptide and treatment for HIV-1 infection
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
JP5933894B2
(ja)
|
2007-09-14 |
2016-06-15 |
アディマブ， エルエルシー |
合理的に設計された、合成抗体ライブラリおよびその使用
|
|
WO2009143865A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
WO2009143864A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
|
|
WO2010072228A1
(en)
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
|
JP5457813B2
(ja)
*
|
2009-12-16 |
2014-04-02 |
ルネサスエレクトロニクス株式会社 |
Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
|
|
WO2011160653A1
(en)
|
2010-06-21 |
2011-12-29 |
Xigen S.A. |
Novel jnk inhibitor molecules
|
|
KR102810907B1
(ko)
|
2010-07-16 |
2025-05-21 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
CA2807036C
(en)
|
2010-10-14 |
2018-01-16 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
|
|
WO2013091670A1
(en)
|
2011-12-21 |
2013-06-27 |
Xigen S.A. |
Novel jnk inhibitor molecules for treatment of various diseases
|
|
EP2903611A4
(en)
*
|
2012-10-04 |
2016-11-16 |
Oyagen Inc |
SMALL MOLECULES AS ANTI-HIV AGENTS FOR INTERRUPTING THE VIF SELF-ASSOCIATION AND METHOD FOR USE THEREOF
|
|
WO2014210082A2
(en)
*
|
2013-06-24 |
2014-12-31 |
Oyagen, Inc. |
Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
|
|
CN105307670A
(zh)
|
2013-06-26 |
2016-02-03 |
埃克西金炎症有限公司 |
Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途
|
|
WO2015197097A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use for jnk inhibitor molecules for treatment of various diseases
|
|
WO2014206427A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
EP3565554A4
(en)
|
2017-01-04 |
2020-08-19 |
Oyagen, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
|
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|